Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

How we can help you

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.

OUR PRODUCTS

EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2026 and the only single view of the risk and return of the R&D landscape from EvaluatePharma Vision.

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

July 03, 2020

Roche and Lilly most vested in research

The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.

July 02, 2020

Covid-19 divides the biggest medtechs

Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.

July 01, 2020

Covid-19 vaccines remain hot – in spite of Inovio

July 01, 2020

Akero continues to pull ahead of Nash rivals

July 01, 2020

Evaluate's COVID-19 Update

Evaluate radically transforms your confidence in strategic portfolio decisions.

Roche and Lilly most vested in research

Covid-19 divides the biggest medtechs

Covid-19 vaccines remain hot – in spite of Inovio

Akero continues to pull ahead of Nash rivals

Go or no go? Pandemic looms over FDA timelines